Clinical Trial Update: A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 randomized study comparing AGS-16C3F versus Axitinib in metastatic renal cell carcinoma has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AGS-16C3F
• Axitinib (Axitinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-23